



CAP STATEMENT ON WHITE HOUSE ANNOUNCEMENT OF SECTION 232 TRADE LAW

APRIL 2, 2026

Today, the White House announced it would exercise its authority under Section 232 of U.S. trade law to impose a 100% tariff on pharmaceutical products imported into the United States, Tony Zagotta, President, Center for American Principles issued the following statement in response:

April 2, 2026, Washington, DC – The Center for American Principles (CAP) is committed to free enterprise as a foundational underpinning of U.S. economic dynamism, technological leadership, and global competitiveness. On principle, CAP views government intervention in markets with skepticism and tariffs are no exception. The tariffs announced today will raise the price of pharmaceutical products and inputs that are critical to the health and well-being of American citizens.

As CAP’s in-depth [Issue Brief](#) on pharmaceutical tariffs explains: “Biopharmaceutical innovators navigate complex supply chains to deliver breakthrough medicines to American patients. A holistic strategy to re-shore critical production capabilities and secure global supply chains with trusted partners can boost U.S. healthcare resilience. A tariff-only policy will raise costs, interrupt supplies, and create shortages.”

The White House has previously signed pricing deals that exempt some large U.S. pharmaceutical companies from the 232 tariff measure; however, small and medium-sized biotech firms at the heart of the U.S. biopharmaceutical innovation ecosystem remain directly in the cross-hairs. Start-up and mid-cap health innovators, who must continuously raise investment capital to advance research through costly clinical trials, are the ones who can least afford to pay a tax on their innovation or re-engineer their disrupted supply chains.

###

The Center for American Principles is a 501(c)(4) non-profit issue advocacy organization that advances sound policy solutions based on core principles to tackle the country’s most critical challenges. (www.centerforamericanprinciples.org)